Fulcrum Therapeutics Inc Cash Flow-to-Debt Ratio
Fulcrum Therapeutics Inc cash flow-to-debt ratio. Fulcrum Therapeutics Inc (FULC) has a Cash Flow-to-Debt Ratio of -0.86x as of September 2025, meaning its operating cash flow of $-14.19 Million could theoretically repay -1% of its total liabilities ($16.49 Million) in one year. Check earnings quality score of Fulcrum Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Fulcrum Therapeutics Inc (2017–2024)
Cash flow-to-debt ratio of Fulcrum Therapeutics Inc from 2017 to 2024. Historical debt coverage capacity for Fulcrum Therapeutics Inc across 8 annual periods. Check FULC cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Fulcrum Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2017–2024)
Fulcrum Therapeutics Inc cash flow-to-debt ratio by year from 2017 to 2024. Year-by-year debt coverage analysis for Fulcrum Therapeutics Inc. For the full cash flow conversion analysis, see cash flow conversion of Fulcrum Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.13x | $-2.22 Million | $17.68 Million | ▲ +96.9% |
| 2023 | -4.04x | $-90.97 Million | $22.50 Million | ▼ -15.6% |
| 2022 | -3.50x | $-97.05 Million | $27.74 Million | ▼ -4.6% |
| 2021 | -3.35x | $-78.48 Million | $23.46 Million | ▼ -114.4% |
| 2020 | -1.56x | $-53.66 Million | $34.40 Million | ▲ +8.0% |
| 2019 | -1.70x | $-39.48 Million | $23.29 Million | ▲ +26.6% |
| 2018 | -2.31x | $-22.56 Million | $9.77 Million | ▲ +65.3% |
| 2017 | -6.65x | $-20.07 Million | $3.02 Million | — |